In addition, a high FoxP3 + TIL count was associated with an inferior outcome in patients with HER2 + Luminal B breast cancer, but not in the HER2 + /HR-negative subgroup, highlighting the difference between these subgroups. This evidence concerns the gene ERBB2 and breast carcinoma.